In triple-negative breast cancer (TNBC), VM capacity statistically correlates with CD133 CSCs marker expression [108], and this co-relation was also demonstrated in other tumors like uveal and cutaneous melanoma, gliomas, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC) [108–110]. This evidence concerns the gene PROM1 and hepatocellular carcinoma.